This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Association of the British Pharmaceutical Industry (ABPI) has welcomed the proposed changes, highlighting their potential to support talent development in areas such as advanced manufacturing, digital skills, and emerging biotechnologies. billion in 2017/18 to 2.5 billion in 2023/24.
Belgian anti-trust regulators are probing Roche over concerns that the drug company took steps to delay the entry of biosimilar versions of two of its cancer medicines. The agency also maintained Roche disseminated “erroneous information” about using biosimilars in combination therapy.
billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.
Innoviva has signed a definitive merger agreement for the acquisition of all of the outstanding shares of La Jolla PharmaceuticalCompany for $6.23 The lead product of the company, Giapreza (angiotensin II) obtained the Food and Drug Administration (FDA) approval in December 2017.
Separately, the drugmaker agreed to pay $25 million to settle charges of participating in a price-fixing scheme with other generic companies. At the same time, Teva steadily raised the price of its drug by thousands of dollars. At the same time, Teva steadily raised the price of its drug by thousands of dollars.
As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions.
WASHINGTON — Pharmaceutical giant AbbVie paid health care providers roughly $145.7 The massive sum spent by AbbVie, the maker of the mega blockbuster anti-inflammatory drug Humira, is the most a pharmaceuticalcompany has spent on marketing to doctors since such data became available in 2017.
Thanks to changes in tax law six years ago, several of the largest pharmaceuticalcompanies saw their tax rates fall substantially, but they also reported that most of their profits were shifted offshore in an effort to avoid paying U.S. In 2017, a new law was passed that permanently lowered corporate tax rates from 35% to 21%.
The pandemic has ushered in a number of major changes to healthcare systems, notably in the ways in which pharmaceuticalcompanies communicate, visit and engage with physicians. Florent Edouard is the global head of commercial excellence at Grünenthal Group , a pharmaceuticalcompany headquartered in Germany and specialised in pain.
The massive sum spent by the company, which makes the blockbuster Humira anti-inflammatory drug, is the most a pharmaceuticalcompany has doled out on marketing to doctors since such data became available in 2017. AbbVie paid health care providers roughly $145.7
The pandemic has triggered a change in how pharmaceuticalcompanies are engaging with healthcare professionals. When IQVIA polled non COVID-19 treating Italian HCPs in March when the crisis was at its worst, it asked HCPs if they still welcomed pharmaceuticalcompany engagement during the crisis. The answer was yes.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content